Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Favorable Outcome of Older Patients with AML and a Favorable Genotype NPM1mut FLT3-ITD Treated with Intensive Chemotherapy: A Subgroup Analysis of Cetlam Protocol 2003 & 2012

Marta Pratcorona, Jordi Lopez-Pardo, MD, Ana Garrido, MD, Salut Brunet, MD PhD, Josep-Maria Ribera, MD PhD, Mar Tormo, MD PhD, Lourdes Escoda, MD PhD, Olga Salamero, Montserrat Arnan, MD PhD, David Gallardo, MD, Joan Bargay, MD, Montserrat Hoyos, PhD, Marina Diaz-Beya, MD PhD, Ruth M Risueño, Josep F. Nomdedeu, MD PhD, Jorge Sierra, MD PhD, Jordi Esteve, MD PhD

Blood (2015) 126 (23): 2511.

https://doi.org/10.1182/blood.V126.23.2511.2511

Published: 2015

Journal Articles

Autologous Activated and Expanded Natural Killer Cells Kill Clonogenic Myeloma Cells: A New Therapeutic Option for Multiple Myeloma

Alejandra Leivas, Graduate Student, Ruth M Risueño, PhD, Antonio Pérez-Martínez, MD PhD, María Jesús Blanchard, MD, Dario Campana, MD PhD, Juan José Lahuerta, MD PhD, Joaquín Martínez-López, MD PhD

Blood (2014) 124 (21): 3467.

https://doi.org/10.1182/blood.V124.21.3467.3467

Published: 2014

Journal Articles

The LincRNA HOTAIRM1 , Located in the HOXA genomic Region , impacts Prognosis in Acute Myeloid Leukemia and Is Associated with a Distinctive microRNA Signature

Marina Díaz-Beyá, MD PhD, Alfons Navarro, PhD, Salut Brunet, MD PhD, Josep F Nomdedeu, MD, Anna Cordeiro, Msc, Marta Pratcorona, MD PhD, Meritxell Nomdedeu, MD PhD, Ruth M Risueño, PhD, Josep-Maria Ribera, MD PhD, Mar Tormo, MDPhD, Rafael F. Duarte, MD PhD, Olga Salamero, MD, Lourdes Escoda, MD, David Gallardo, MD PhD, Carmen Pedro, MD, Josep M Marti-Tutusaus, Jorge Sierra, MD, Mariano Monzó, MD PhD, Jordi Esteve, MD PhD

Blood (2014) 124 (21): 1003.

https://doi.org/10.1182/blood.V124.21.1003.1003

Published: 2014

Journal Articles

Treatment With G-CSF Reduces Acute Myeloid Leukemia (AML) Blasts Viability In Presence Of Bone Marrow Stroma

Meritxell Nomdedeu, MD, PhD, Marta Pratcorona, MD, Marina Díaz-Beyá, MD, Xavier Calvo, MD, Mari Carmen Lara-Castillo, PhD, Daniel Esteban, MD, Maria Rozman, MD, PhD, Dolors Costa, PhD, Jordi Esteve, MD, PhD, Ruth M. Risueño, PhD

Blood (2013) 122 (21): 1422.

https://doi.org/10.1182/blood.V122.21.1422.1422

Published: 2013

Journal Articles

BAALC -Associated Mir-3151 Is An Independent Prognostic Factor In Younger Patients With Intermediate-Risk Cytogenetic Acute Myeloid Leukemia

Marina Díaz-Beyá, MD, Alfons Navarro, PhD, Marta Pratcorona, MD, Salut Brunet, MD, PhD, Josep F Nomdedeu, MD, Josep-Maria Ribera, MD, PhD, Mar Tormo, MD, Rafael F. Duarte, MD, PhD, Olga Salamero, MD, David Gallardo, MD, PhD, Lourdes Escoda, Meritxell Nomdedeu, MD, PhD, Ruth M Risueño, PhD, Montserrat Hoyos, Francisco Cervantes, MD, PhD, Jorge Sierra, MD, PhD, Mariano Monzó, MD, PhD, Jordi Esteve, MD, PhD

Blood (2013) 122 (21): 2577.

https://doi.org/10.1182/blood.V122.21.2577.2577

Published: 2013

Journal Articles

DNMT3A Mutation May Add Prognostic Value To Patients With Acute Myeloid Leukemia Of Intermediate Cytogenetic Risk Harboring a Favorable Genetic Profile Of NPM1 , FLT3 -ITD and CEBPA

Marta Pratcorona, MD, Marina Díaz-Beyá, MD, Meritxell Nomdedeu, MD, PhD, Maria Rozman, MD, Ruth M Risueño, PhD, Jordi Esteve, MD, PhD

Blood (2013) 122 (21): 1339.

https://doi.org/10.1182/blood.V122.21.1339.1339

Published: 2013

Journal Articles

Identification of T-lymphocytic leukemia–initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease

Ruth M. Risueño, Clinton J. V. Campbell, Steve Dingwall, Marilyne Levadoux-Martin, Brian Leber, Anargyros Xenocostas, Mickie Bhatia

Blood (2011) 117 (26): 7112–7120.

https://doi.org/10.1182/blood-2011-01-329078

Published: 2011

Includes: Supplemental data

Journal Articles

Targeting LSCs: powering an old tool

Simona Salati, Ruth M. Risueno, Mickie Bhatia

Blood (2008) 111 (12): 5423–5424.

https://doi.org/10.1182/blood-2008-03-144063

Published: 2008

NARROW

Favorable Outcome of Older Patients with AML and a Favorable Genotype NPM1mut FLT3-ITD Treated with Intensive Chemotherapy: A Subgroup Analysis of Cetlam Protocol 2003 & 2012

Autologous Activated and Expanded Natural Killer Cells Kill Clonogenic Myeloma Cells: A New Therapeutic Option for Multiple Myeloma

The LincRNA HOTAIRM1 , Located in the HOXA genomic Region , impacts Prognosis in Acute Myeloid Leukemia and Is Associated with a Distinctive microRNA Signature

Treatment With G-CSF Reduces Acute Myeloid Leukemia (AML) Blasts Viability In Presence Of Bone Marrow Stroma

BAALC -Associated Mir-3151 Is An Independent Prognostic Factor In Younger Patients With Intermediate-Risk Cytogenetic Acute Myeloid Leukemia

DNMT3A Mutation May Add Prognostic Value To Patients With Acute Myeloid Leukemia Of Intermediate Cytogenetic Risk Harboring a Favorable Genetic Profile Of NPM1 , FLT3 -ITD and CEBPA

Identification of T-lymphocytic leukemia–initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease

Targeting LSCs: powering an old tool

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only